DC Circ. Won't Revive FTC's Endo-Impax Deal Suit
A D.C. Circuit panel refused Friday to revive a Federal Trade Commission lawsuit targeting an opioid medication settlement between Endo Pharmaceuticals and Impax, concluding the license brandmaker Endo granted for Impax...To view the full article, register now.
Already a subscriber? Click here to view full article